82 related articles for article (PubMed ID: 3053997)
21. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury.
Aronson FR; Libby P; Brandon EP; Janicka MW; Mier JW
J Immunol; 1988 Jul; 141(1):158-63. PubMed ID: 3259966
[TBL] [Abstract][Full Text] [Related]
22. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
23. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
25. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
27. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Hank JA; Sosman JA; Kohler PC; Bechhofer R; Storer B; Sondel PM
J Biol Response Mod; 1990 Feb; 9(1):5-14. PubMed ID: 2181071
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
29. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
30. The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones.
Schmidt RE; Hercend T; Fox DA; Bensussan A; Bartley G; Daley JF; Schlossman SF; Reinherz EL; Ritz J
J Immunol; 1985 Jul; 135(1):672-8. PubMed ID: 3923116
[TBL] [Abstract][Full Text] [Related]
31. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Hank JA; Kohler PC; Weil-Hillman G; Rosenthal N; Moore KH; Storer B; Minkoff D; Bradshaw J; Bechhofer R; Sondel PM
Cancer Res; 1988 Apr; 48(7):1965-71. PubMed ID: 3258180
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
Botzler C; Kis K; Issels R; Multhoff G
Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
[TBL] [Abstract][Full Text] [Related]
33. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
[TBL] [Abstract][Full Text] [Related]
34. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
35. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
36. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
37. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
38. Local and systemic immune response to inactivated Candida albicans in mice.
Scaringi L; Rosati E; Cornacchione P; Fettucciari K; Sabatini R; Biondi R; Mezzasoma L; Valiani M; D'Errico P; Marconi P
Nat Immun; 1995 Sep; 14(5-6):234-49. PubMed ID: 8933818
[TBL] [Abstract][Full Text] [Related]
39. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
40. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]